Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens

International Journal of Urology

Volumn 18, Issue 5, 2011, Pages 350-357

  Joung, Jae Young ^a   Kwon, Whi An ^a   Cho, In Chang ^a   Kim, Eun Kyung ^a   Park, Sohee ^a   Yoon, Hyekyoung ^a   Seo, Ho Kyung ^a   Chung, Jinsoo ^a   Park, Weon Seo ^a   Lee, Kang Hyun ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Paclitaxel; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; VINBLASTINE; WARFARIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CYSTECTOMY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROURETERECTOMY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENTAMICINS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 79955100486     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02735.x     Document Type: Article

References (22)

1. Suyama T, Ueda T, Fukasawa S etal. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J. Clin. Oncol. 2009; 39: 244-50.
2. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1, 026 cases. J. Urol. 1997; 158: 393-9.
3. Stein JP, Lieskovsky G, Cote R etal. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J. Clin. Oncol. 2001; 19: 666-75.
4. Bamias A, Tiliakos I, Karali MD, Dimopoulos MA. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann. Oncol. 2006; 17: 553-61.
5. Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J. Clin. Oncol. 2006; 24: 5545-51.
6. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat. Rev. 2007; 33: 177-90.
7. von der Maase H, Sengelov L, Roberts JT etal. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005; 23: 4602-8.
8. Han KS, Joung JY, Kim TS etal. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br. J. Cancer 2008; 98: 86-90.
9. Kanai K, Kikuchi E, Ohigashi T etal. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int. J. Clin. Oncol. 2008; 13: 510-14.
10. Kouno T, Ando M, Yonemori K etal. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur. Urol. 2007; 52: 1115-22.
11. Matsumoto K, Irie A, Satoh T, Okazaki M, Iwamura M, Baba S. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int. J. Urol. 2007; 14: 1000-4; discussion 1004.
12. Smith DC, Mackler NJ, Dunn RL etal. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J. Urol. 2008; 180: 2384-8; discussion 2388.
13. Uhm JE, Lim HY, Kim WS etal. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 2007; 9: 18-22.
14. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205-16.
15. Bellmunt J, Theodore C, Demkov T etal. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009; 27: 4454-61.
16. Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr. Opin. Urol. 2009; 19: 533-9.
17. Roth BJ, Dreicer R, Einhorn LH etal. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 1994; 12: 2264-70.
18. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 2002; 20: 937-40.
19. Sweeney CJ, Williams SD, Finch DE etal. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999; 86: 514-18.
20. Vaishampayan UN, Faulkner JR, Small EJ etal. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 2005; 104: 1627-32.
21. Soga N, Onishi T, Arima K, Sugimura Y. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int. J. Urol. 2007; 14: 828-32.
22. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin. Ann. Oncol. 2003; 14: 500.